Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx Limited (NYSE AMERICAN: VNRX) provided a business update on March 30, 2022, announcing a global licensing deal with Heska Corporation for the Nu.Q® Vet Cancer Screening Test. This deal includes a $10 million upfront payment and potential milestone payments of up to $18 million. Volition reported a net loss of $27 million for 2021, largely due to non-cash items and increased staffing costs, with cash reserves totaling $20.6 million. The company continues to advance its product development and has a total addressable market estimated at $70 billion.
VolitionRx Limited (NYSE AMERICAN: VNRX) has entered an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) to market its Nu.Q® Vet Cancer Screening Test for companion animals. This deal includes a $10 million upfront payment and up to $18 million for milestone achievements. The test aims to enhance early cancer detection in dogs and cats, targeting a global market estimated at $11 billion. Administrating this test will be facilitated through Heska's proprietary analyzers, making it accessible and affordable for veterinarians.
Heska Corporation (NASDAQ: HSKA) has entered an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) to commercialize the Nu.Q® Vet Cancer Screening Test for companion animals. This test aims to provide veterinarians with the ability to screen pets for cancer at the point of care. With an estimated $11 billion market for canine and feline cancer screening, this innovative solution is expected to greatly enhance early detection and treatment for pets, benefiting both healthcare outcomes and pet owners.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call scheduled for March 31, 2022, at 08:00 a.m. Eastern time to discuss its full fiscal year 2021 financial and operating results and provide a business update. The call will feature CEO Cameron Reynolds and other executives discussing recent developments and ongoing clinical trials. Investors can access a live audio webcast on the company’s investor relations page. A replay of the call will be available until April 14, 2022.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the results of two large-scale clinical studies demonstrating that its Nu.Q® assays, in conjunction with the Fecal Immunochemical Test (FIT), can significantly enhance the detection of colorectal cancer and advanced adenomas in symptomatic patients, potentially reducing unnecessary colonoscopies by up to 28%. The studies involved 476 symptomatic and 520 asymptomatic patients, showing improved results over traditional FIT methods. Findings will be presented at ASCO GI 2022, emphasizing the importance of early diagnosis in colorectal cancer management.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed SAGE Healthcare Private Limited as a non-exclusive licensee and distributor for its Nu.Q® Vet Cancer Screening Test in Singapore. The test launch is slated for Q1 2022, with plans for further expansion across Asia. Volition aims to establish similar agreements globally to enhance accessibility to the Nu.Q® Test. Ongoing negotiations with multinational veterinary companies are progressing, with potential contracts expected soon.
VolitionRx Limited (VNRX) reported its third quarter financial results for 2021, highlighting a cash position of $22.9 million and an average monthly cash burn rate of $1.7 million. The company is in advanced negotiations with three major veterinary firms for licensing agreements and has expanded its intellectual property assets. Despite a net loss of $7.2 million this quarter, increased from $5.6 million in the prior quarter, Volition is optimistic about its Nu.Q® products' potential and upcoming launches. A conference call is scheduled for November 11, 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call on November 11, 2021, at 8:00 a.m. Eastern time to discuss its third quarter 2021 financial results and provide a business update. The call will include updates on ongoing clinical trials and key events from Q3 2021. CEO Cameron Reynolds, along with other executives, will lead the discussion. Investors can access a live audio webcast from their investor relations page. A telephone replay will be available until November 25, 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented two significant abstracts at the 2021 Veterinary Cancer Society Conference. The first highlights the effectiveness of Nu.Q® in monitoring disease response and progression in cancer-bearing dogs, showing potential for early identification of remission. The second abstract introduces Nu.Q® Capture, an enrichment tool for analyzing circulating nucleosomes in dogs with lymphoma. These advancements pave the way for a second Nu.Q® Vet product launch planned for 2022, reinforcing Volition's commitment to improving cancer diagnostics in veterinary medicine.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported strong progress in its second quarter ended June 30, 2021, highlighting a solid balance sheet with $27.9 million in cash. The company has expanded its intellectual property portfolio, added key personnel, and published significant clinical research. Notably, the beta launch of the Nu.Q® Vet platform received high interest for licensing. However, they reported a net loss of $5.6 million for the quarter and continue to face operational challenges due to the pandemic.
FAQ
What is the current stock price of VolitionRX (VNRX)?
What is the market cap of VolitionRX (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
